The Effects of Canagliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, on Mineral Metabolism and Bone in Patients With Type 2 Diabetes Mellitus.

CONCLUSIONS: Across clinical studies, canagliflozin did not meaningfully affect calcium homeostasis or hormones regulating calcium homeostasis. Increases in bone turnover markers and decreases in BMD at the total hip, but not at other sites, that correlated with weight loss were seen with canagliflozin. Canagliflozin was associated with a higher fracture incidence within 12 weeks and primarily in distal extremities. Data from ongoing canagliflozin studies will provide additional information on fracture risk. PMID: 27046479 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research